CVI
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Other Versions of this Article:
CVI.00087-07v1
14/8/1005    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Duthie, M. S.
Right arrow Articles by Kahn, S. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Duthie, M. S.
Right arrow Articles by Kahn, S. J.

 Previous Article  |  Next Article 

Clinical and Vaccine Immunology, August 2007, p. 1005-1012, Vol. 14, No. 8
1071-412X/07/$08.00+0     doi:10.1128/CVI.00087-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Parasite-Induced Chronic Inflammation Is Not Exacerbated by Immunotherapy before or during Trypanosoma cruzi Infection{triangledown}

Malcolm S. Duthie, Maria Kahn, Arsen Zakayan, Maria White, and Stuart J. Kahn*

Infectious Disease Research Institute, 1124 Columbia St., Suite 400, Seattle, Washington 98104

Received 17 February 2007/ Returned for modification 9 May 2007/ Accepted 23 May 2007

Trypanosoma cruzi infection causes Chagas' disease, a chronic inflammatory disease. The specific inflammatory responses that cause Chagas' disease remain unclear, but data argue that parasites that persist in the host stimulate chronic self-damaging immune responses. Because T. cruzi appears to stimulate self-damaging responses, the enthusiasm to develop vaccines that boost antiparasite responses that might increase self-damaging responses has been limited. We previously demonstrated that immunization with a T. cruzi trans-sialidase protein or adoptive transfer of trans-sialidase-specific T-cell clones decreased parasitemia, morbidity, and mortality. Here we report that immunization or adoptive transfer with the protein or clones, before or during T. cruzi infection, boosts the anti-T. cruzi immune response without exacerbating acute or chronic tissue inflammation. These results argue that prophylactic and therapeutic immunotherapy for Chagas' disease can be developed safely.

* Corresponding author. Mailing address: IDRI, 1124 Columbia St., Suite 400, Seattle, WA 98104. Phone: (206) 330-2509. Fax: (206) 381-3678. E-mail: skahn{at}idri.org

{triangledown} Published ahead of print on 30 May 2007.

Clinical and Vaccine Immunology, August 2007, p. 1005-1012, Vol. 14, No. 8
1071-412X/07/$08.00+0     doi:10.1128/CVI.00087-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.





Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Antimicrob. Agents Chemother. Clin. Microbiol. Rev. Infect. Immun.
J. Clin. Microbiol. J. Virol. ALL ASM JOURNALS

Copyright © 2007 by the American Society for Microbiology. All rights reserved.